RSV LID ΔM2-2 1030s vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Respiratory Syncytial Virus Infections

Phase 1

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

CompletedNCT02794870

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2016-07-15End: 2017-07-07Updated: 2018-08-27

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

CompletedNCT02952339

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2016-08-31End: 2017-07-31Target: 33Updated: 2018-02-13